WO2000043025A1 - Pharmaceutical preparation for treating viral infections - Google Patents

Pharmaceutical preparation for treating viral infections Download PDF

Info

Publication number
WO2000043025A1
WO2000043025A1 PCT/IB2000/000045 IB0000045W WO0043025A1 WO 2000043025 A1 WO2000043025 A1 WO 2000043025A1 IB 0000045 W IB0000045 W IB 0000045W WO 0043025 A1 WO0043025 A1 WO 0043025A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
vernonia
oligocephalus
powder
pharmaceutical preparation
Prior art date
Application number
PCT/IB2000/000045
Other languages
French (fr)
Inventor
Willem Adriaan Van Zyl
Original Assignee
Albrecht, Carl, Franz, De Vos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albrecht, Carl, Franz, De Vos filed Critical Albrecht, Carl, Franz, De Vos
Priority to AU19969/00A priority Critical patent/AU1996900A/en
Priority to GB0117819A priority patent/GB2362827B/en
Publication of WO2000043025A1 publication Critical patent/WO2000043025A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to a pharmaceutical preparation for treating viral infections.
  • the invention relates to a pharmaceutical preparation for treating viral infections which also can be utilized as an immune stimulant.
  • Immune deficiency is due to a failure of the body's immune system, which normally protects the body against infecting organisms and, for instance, the development of cancer.
  • AIDS abbreviated immune deficiency syndrome
  • other immune deficiency disorders increase susceptibility to certain type of diseases, cancer and recurrent or persistent infections.
  • the preparation may be in a tablet form.
  • Each tablet may contain 50-800mg of the powder, e.g. 275mg of the powder.
  • the dosage for capsules was that a capsule was taken 3 times per day, i.e. every 8 hours before or after meals.
  • HIV RNA Of particular importance is the drop in HIV RNA from 8844 to less than 500 over a period of a year. Also significant is the maintenance of CD4 counts and the increase in total lymphocytes. There is apparently very recent evidence that a subset of CD8 cells are important in counteracting HIV infection. In this regard note that the CD8 absolute numbers also increased which indicate that immune stimulation and metabolism are increased.
  • CVID is immunologically heterogenous.
  • CVID results in distinctive categories of disease complications including 1 ) acute and recurring bacterial infections, 2) Autoimmune disease, 3) gastrointestinal disease, 4) granulomatous disease, 5) Cancer, 6) hepatitis.
  • Autoimmune Hemolytic Anemia Idiopathic thrombocytopenic purpura, Rheumatoid arthritis, Sicca syndrome, Pernicious anemia, Crohn's disease, Ulcerative colitis, Sprue-like disease, Anti IgA antibodies, Alopecia totalis, Neutropenia, Juvenile rheumatoid arthritis, Primary biliary cirrhosis, Mixed connective tissue disease, Hyperthyroidism.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Immune deficiency and viral infection is of great concern throughout the world. Immune deficiency is due to a failure of the body's immune system, which normally protects the body against infecting organisms and, for instance, the development of cancer. AIDS (acquired immune deficiency syndrome) and other immune deficiency disorders increase susceptibility to certain type of diseases, cancer and recurrent or persistent infections. The invention suggests a novel pharmaceutical preparation for treating viral infections and which also can be utilized as an immune stimulant. According to the invention a pharmaceutical preparation for treating viral infections includes a powder or an extract derived from Vernonia Oligocephalus plant species, particularly from aerial parts. 8α-(2-hydroxymethyl acryloyloxy)-hirsutinolide-13-0-acetate may be the extract derived from the Vernonia Oligocephalus plant species.

Description

Pharmaceutical preparation for treating viral infections.
FIELD OF INVENTION
The present invention relates to a pharmaceutical preparation for treating viral infections.
More particularly, the invention relates to a pharmaceutical preparation for treating viral infections which also can be utilized as an immune stimulant.
BACKGROUND TO INVENTION
For many years immune deficiency and viral infection have been a great concern throughout the world. Immune deficiency is due to a failure of the body's immune system, which normally protects the body against infecting organisms and, for instance, the development of cancer. AIDS (acquired immune deficiency syndrome) and other immune deficiency disorders increase susceptibility to certain type of diseases, cancer and recurrent or persistent infections.
It is an object of the invention to suggest a novel pharmaceutical preparation for treating viral infections.
SUMMARY OF INVENTION
According to the invention, a pharmaceutical preparation for treating viral infections includes powder derived from Vernonia Oligocephalus plant species.
The preparation may include powder derived from aerial parts of Vernonia Oligocephalus plant species. The preparation may be in powder form.
Also according to the invention, a pharmaceutical preparation for treating viral infections includes an extract derived from Vernonia Oligocephalus plant species.
8α-(2-hydroxymethyl acryloyloxy)-hirsutinolide-13-0-acetate may be the extract derived from the Vernonia Oligocephalus plant species.
The preparation may be in a tablet form.
Each tablet may contain 50-800mg of the powder, e.g. 275mg of the powder.
The preparation may be in a capsule form.
Each capsule may contain 50-800mg of the powder, e.g. 275mg of the powder.
The preparation may be in an ointment form.
The ointment may contain about 0.2-0.8g/ml, e.g. 0.4g/ml of the extract incorporated in a cream base.
The preparation may be in a tonic form.
The tonic may contain about 0.1-0.8g/ml of the extract in about 30-80% alcohol.
The tonic may contain about 0,2g/ml of the extract in about 40% alcohol. DETAILED DESCRIPTION OF PREPARATION OF PRODUCT AND TESTS CONDUCTED
Preparation of product.
The natural plant material, consisting of 100% dried aerial Vernonia Oligocephalus, is dried and milled with a small hammer mill. Only the aerial parts of the plant are used.
Thereafter the powder is used to prepare the following application forms:
Capsules: White capsules, size "0". Approximately 500mg of dried powdered plant material per capsule. For oral application.
Cream: Tubes of 100ml each approximately 0.4g/ml incorporated into a cream base at 50:50 ratio. For topical application only.
Tonic/tincture: 50ml bottles. Approximately 0.2g/ml in 40% alcohol. For oral application only.
The dosage for capsules (275mg of powdered plant material in each capsule) was that a capsule was taken 3 times per day, i.e. every 8 hours before or after meals.
Tests had revealed no adverse effects in humans.
The treatment was administered orally to a patient with laboratory confirmed HIV infection (a male 46 years of age).
When the first blood samples were taken, the patient had already been taking the extracts. The (CD8+) cell count, the (CD8+) cell percentage as well as the maintenance of the total lymphocyte count in accordance with the (CD8+) cell count and cell percentage are significant factors.
The blood screening was taken initially and thereafter at regular intervals, the final screening taking place about one year after commencement of the treatment.
The results are as set out below:
Blood screeninα 1.
T-LYMPHOCYTE
SUBSETS NORMAL
Total lymphocyte count 2674 /cmm [1 000 - 4 000]
Helper (CD4+) Cell count. 348 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 13 % [30 - 60]
Suppr. (CD8+) Cell count. 1765 /cmm [400 - 1 000]
Suppr. (CD8+) Cell percentage 66 % [22 - 51]
CD4+ : CD8+ ratio 0.2 [1.0 - 2.0]
Viral load:
Parameter Result: Reference Ranαe:
HIV-1 viral load 8844 Not applicable
Blood screening 2
T-LYMPHOCYTE SUBSETS NORMAL
Total lymphocyte count 3120 /cmm [1 000 - 4 000]
Helper (CD4+) Cell count. 437 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 14 % [30 - 60] Suppr. (CD8+) Cell count. 2122 /cmm [400 - 1 000]
Suppr. (CD8+) Cell percentage 68 % [22 - 51] CD4+ : CD8+ ratio 0.2 [1.0 - 2.0]
Viral load: Parameter Result: Reference Ranαe:
HIV-1 viral load 13780 Not applicable
Blood screeninα 3
T-LYMPHOCYTE SUBSETS NORMAL
Total lymphocyte count 3438 /cmm [1 000 - 4 000]
Helper (CD4+) Cell count. 447 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 13 % [30 - 60]
Suppr. (CD8+) Cell count. 2303 /cmm [400 - 1 000]
Suppr. (CD8+) Cell percentage 67 % [22 - 51]
CD4+ : CD8+ ratio 0.2 [1.0 - 2.0]
Viral load:
Parameter Result: Reference Ranαe:
HIV-1 viral load 17420 Not applicable Blood screeninα 4
T-LYMPHOCYTE SUBSETS NORMAL Total lymphocyte count 2804 /cmm [1 000 - 4 000] Helper (CD4+) Cell count. 336 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 12 % [30 - 60] Suppr. (CD8+) Cell count. 1738 /cmm [400 - 1 000]
Suppr. (CD8+) Cell percentage 62 % [22 - 51] CD4+ : CD8+ ratio 0.2 [1.0 - 2.0] Viral load:
Parameter Result: Reference Ranαe:
HIV-1 viral load 3684 Not applicable
Blood screeninα 5
T-LYMPHOCYTE SUBSETS NORMAL
Total lymphocyte count 3105 /cmm [1 000 - 4 000]
Helper (CD4+) Cell count. 342 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 11 % [30 - 60] Suppr. (CD8+) Cell count. 2111 /cmm [400 - 1 000] Suppr. (CD8+) Cell percentage 68 % [22 - 51] CD4+ : CD8+ ratio 0.2 [1.0 - 2.0]
Viral load:
Parameter Result: Reference Ranαe:
HIV-1 viral load 5716 Not applicable Blood screeninα 6
T-LYMPHOCYTE SUBSETS NORMAL
Total lymphocyte count 3108 /cmm [1 000 - 4 000]
Helper (CD4+) Cell count. 342 /cmm [600 - 1 500]
Helper (CD4+) Cell percentage 11 % [30 - 60]
Suppr. (CD8+) Cell count. 2051 /cmm [400 - 1 000]
Suppr. (CD8+) Cell percentage 66 % [22 - 51]
CD4+ : CD8+ ratio 0.2 [1.0 - 2.0]
Viral load:
Parameter Result: Reference Ranαe:
HIV-1 viral load <500 Not applicable
The above tests are summarized in the table below:
Figure imgf000009_0001
Of particular importance is the drop in HIV RNA from 8844 to less than 500 over a period of a year. Also significant is the maintenance of CD4 counts and the increase in total lymphocytes. There is apparently very recent evidence that a subset of CD8 cells are important in counteracting HIV infection. In this regard note that the CD8 absolute numbers also increased which indicate that immune stimulation and metabolism are increased.
It therefore is to be concluded that:
• HIV RNA decreased progressively
• CD4 remained stable
• CD8 increased
Total lymphocyte counts increased.
Blood test results of patient
Table II:
Figure imgf000010_0001
Figure imgf000011_0001
The above table shows no toxic effects while the patient was being treated.
1) Immune Stimulating and modulating properties discovered:
The combination of the maintenance of the CD4+ cell count, the decrease of HIV viral load, the increase in CD8+ cell count and the increase in the related total lymphocyte count and the lack of toxicity are considered to be of therapeutic benefit for the patient.
2) Anti-viral Activity:
The viral load reduction results, which indicate anti-viral activities against the HIV/AIDS virus, which was obtained from the above research trial are significant, considering that the pharmaceutical preparation applied is not concentrated or enhanced. Thus there is definite indications of antiviral activity present in pharmaceutical preparation according to the invention. Diseases and medical indications that can be treated
It is concluded that the extract from the plant Vernonia Oligocephalus, can be used as an Immune Stimulant/Modulator to aid the body's immune system and used for treatment or assisting in the treatment for:
Common variable Immunodeficiency (CVID):
CVID, which major features are: onset at any age, hypogammaglubulinemia with antibody deficiency, variable defects in cell-mediated immunity, clinical triad - infections, Autoimmune/inflammatory diseases, - Malignancy.
Etiology:
CVID is immunologically heterogenous.
Clinical Manifestations:
CVID results in distinctive categories of disease complications including 1 ) acute and recurring bacterial infections, 2) Autoimmune disease, 3) gastrointestinal disease, 4) granulomatous disease, 5) Cancer, 6) hepatitis.
Infections:
Infections associated with CVID:
Recurrent Bronchitis, Sinusitis, Ototis, Conjunctivitis, Pneumonia, Hepatitits, Meningitis, severe Herpes Zoster, Pneumocystis Carinii.
Autoimmunity:
The most common Autoimmune disease found in this patient population is Autoimmune Hemolytic Anemia, Idiopathic thrombocytopenic purpura, Rheumatoid arthritis, Sicca syndrome, Pernicious anemia, Crohn's disease, Ulcerative colitis, Sprue-like disease, Anti IgA antibodies, Alopecia totalis, Neutropenia, Juvenile rheumatoid arthritis, Primary biliary cirrhosis, Mixed connective tissue disease, Hyperthyroidism.
Cancer:
Malignancies occur in patients with CVID.
Type of cancer in CVID:
Lymphoma, Hodgkin's disease, Adenocarcinoma of the colon, Adenocarcinoma of the stomach, Cancer of the tongue, Squamous-cell carcinoma of the vagina, Adenocarcinoma of the ovary.
Other Immunoglobulin Deficiencies:
Transient hypogammaglobulinemia of infancy, Common variable immunodeficiency, X-linked ammaglobulinemia, IgG subclass deficiency, IgA deficiency.
HIV/AIDS virus infection:
The spectrum of infections that affect HIV positive individuals often indicate a significant deficiency of CD4+ cells. The preparation in accordance with the invention assists the body's natural defense mechanism in protecting the immune system.
The product in accordance with the invention can be used for the treatment of viral diseases and the reduction of viral load due to the known anti-viral activities present in the extract. Diseases and disorders: Virus diseases:
Arbovirus Infections, Chronic Fatigue Syndrome, DNA Virus Infections, Human Viral Hepatitis, Hepatitis B, other RNA Virus Infections, Viral Bronchiolitis, Viral Encephalitis, Viral Meningitis, Viral Pneumonia, Viral Sexually transmitted diseases, Viral skin diseases, Viremia, Zoonoses,
The following Genome type (viruses) can be treated with the aid of the preparation in accordance with the invention:
DNA viruses: dsDNA viruses, ssDNA viruses. Reverse transcriptase RNA viruses: dsRNA viruses, (-)ssRNA viruses, (+)ssRNA viruses. Unassigned viruses, Subviral Agents. Prions, Satellites, Viroids.
General diseases:
Anti-depressant, nervous conditions, alcoholism, liver diseases, general hepatitis, respiratory problems, pneumonia.
General comments:
The active incredient in the Vernonia Oligocephalus plant species may be 8α-(2-hydroxymethyl acryloyloxy)-hirsutinolide-13-0-acetate.
The Vernonia Oligocephalus is also known as Vernonia Oligocephalus (DC) Walp. and the widely used name Vernonia Kraussii Sch. Bip. must be accepted as a synonym thereof.

Claims

PATENT CLAIMS
1. A pharmaceutical preparation for treating viral infections including powder derived from Vernonia Oligocephalus plant species.
2. A preparation as claimed in claim 1 , including powder derived from aerial parts of Vernonia Oligocephalus plant species.
3. A preparation as claimed in claim 1 or claim 2, which is in powder form.
4. A pharmaceutical preparation for treating viral infections including an extract derived from Vernonia Oligocephalus plant species.
5. A preparation as claimed in claim 4, in which 8α-(2-hydroxymethyl acryloyloxy)-hirsutinolide-13-0-acetate is the extract derived from the Vernonia Oligocephalus plant species.
6. A preparation as claimed in any one of the preceding claims, which is in a tablet form.
7. A preparation as claimed in claim 6, in which each tablet contains 50-800mg of the powder.
8. A preparation as claimed in claim 7, in which each tablet contains 275mg of the powder.
9. A preparation as claimed in any one of claims 1 to 5, which is in a capsule form.
10. A preparation as claimed in claim 9, in which each capsule contains 50-800mg of the powder.
11. A preparation as claimed in claim 10, in which each capsule contains 275mg of the powder.
12. A preparation as claimed in any one of claims 1 to 5, which is in an ointment form.
13. A preparation as claimed in claim 12, in which the ointment contains about 0.2-0.8g/ml of the extract incorporated in a cream base.
14. A preparation as claimed in claim 13, in which the ointment contains about 0.4g/ml of the extract incorporated in a cream base.
15. A preparation as claimed in any one of claims 1 to 5, which is in a tonic form.
16. A preparation as claimed in claim 15, in which the tonic contains about 0.1-0.8g/ml of the extract in about 30-80% alcohol.
17. A preparation as claimed in claim 16, in which the tonic contains about 0,2g/ml of the extract in about 40% alcohol.
PCT/IB2000/000045 1999-01-21 2000-01-19 Pharmaceutical preparation for treating viral infections WO2000043025A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU19969/00A AU1996900A (en) 1999-01-21 2000-01-19 Pharmaceutical preparation for treating viral infections
GB0117819A GB2362827B (en) 1999-01-21 2000-01-19 Pharmaceutical preparation for treating viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ZA99417 1999-01-21
ZA99/0417 1999-01-21
ZA99/4671 1999-07-21
ZA994671 1999-07-21

Publications (1)

Publication Number Publication Date
WO2000043025A1 true WO2000043025A1 (en) 2000-07-27

Family

ID=27145141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000045 WO2000043025A1 (en) 1999-01-21 2000-01-19 Pharmaceutical preparation for treating viral infections

Country Status (4)

Country Link
AU (1) AU1996900A (en)
CH (1) CH694687A5 (en)
GB (1) GB2362827B (en)
WO (1) WO2000043025A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113851A2 (en) * 2006-03-31 2007-10-11 Panacea Biotec Ltd. Novel compositions for hair disorders and process of preparation thereof
CN104721509A (en) * 2015-04-05 2015-06-24 四川双鑫生物科技有限公司 Decoction medicine for treating children virus pneumonia and preparation method thereof
CN107233503A (en) * 2017-06-06 2017-10-10 郜宪林 A kind of Chinese medicine composition for alleviating meningitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FERDINAND BOHLMANN ET AL.: "FURTHER GLAUCOLIDES FROM SOUTH AFRICAN VERNONIA SPECIES.", PHYTOCHEMISTRY., vol. 23, no. 8, 1984, PERGAMON PRESS., GB, pages 1795 - 1798, XP000910782, ISSN: 0031-9422 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113851A2 (en) * 2006-03-31 2007-10-11 Panacea Biotec Ltd. Novel compositions for hair disorders and process of preparation thereof
WO2007113851A3 (en) * 2006-03-31 2008-01-03 Panacea Biotec Ltd Novel compositions for hair disorders and process of preparation thereof
CN104721509A (en) * 2015-04-05 2015-06-24 四川双鑫生物科技有限公司 Decoction medicine for treating children virus pneumonia and preparation method thereof
CN107233503A (en) * 2017-06-06 2017-10-10 郜宪林 A kind of Chinese medicine composition for alleviating meningitis

Also Published As

Publication number Publication date
GB2362827A (en) 2001-12-05
AU1996900A (en) 2000-08-07
CH694687A5 (en) 2005-06-15
GB0117819D0 (en) 2001-09-12
GB2362827B (en) 2002-04-03

Similar Documents

Publication Publication Date Title
DE3886710T2 (en) METHOD FOR SELECTIVE INHIBITION OF HIV.
RU2687498C2 (en) Algae extract for use as immunomodulatory agent
Chuang et al. Increased replication of simian immunodeficiency virus in CEM x174 cells by morphine sulfate
AU2011282200B2 (en) Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment
WO2010082798A2 (en) Composition containing extracts of fuscoporia obliqua, ganoderma lucidum and phellinus linteus for promoting the proliferation of hematopoietic stem cells
EP1978980B1 (en) Use of a combination of rosa sp., urtica dioica and tanacetum vulgare extracts, further comprising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for treatment of hiv infections
TWI269656B (en) Therapeutical composition for hepatitis C
RU2073522C1 (en) Medicinal preparation having antivirus effect
CN102551058A (en) Chinese medicinal health-care product with function of enhancing immunity
Eby Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation–a case history and hypothesis
WO2000043025A1 (en) Pharmaceutical preparation for treating viral infections
CN105535964A (en) Double-strand polynucleotide-epsilon-polylysine-sulfuric acid glycan compound with immune regulating function and preparing and using method thereof
JPH11228602A (en) Immune enhancement agent and immune enhancement food
JPH01120284A (en) Incomplete particle of hiv and production thereof
EP0295962B1 (en) Protein-polysaccharide for treating retroviral infections
WO2006015556A1 (en) A antiviral combination and thereof manufacture
WO2011096685A2 (en) Wormwood pill containing 95% of wormwood ethyl alcohol extract that has inactivation efficacy of the h1n1 virus and the h9n2 avian influenza virus
KR100370501B1 (en) Composition for treatment of hepatitis b, containing extract of lonicera japonica thunb
ZA200604983B (en) Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences
WO1999051249A1 (en) Herbal composition for the prophylaxis and treatment of aids
ZA200106431B (en) Pharmaceutical preparation for treating viral infections.
Tuleuhanov et al. Study of hematological parameters of rats at the action of the immunostimulating drug «Flavovir»
RU2089194C1 (en) Method of treatment of chronic generalized viral infection
RU2237484C1 (en) Method for treating hiv-infected patients
KR100346611B1 (en) Therapeutic agent of b type hepatitis containing seconoganoside

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: GB

Ref document number: 200117819

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 19969/00

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase